Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world.
- Author:
Yan-Hua LUO
;
Yan-Ming XIE
;
Wei YANG
;
Yong-Yan WANG
;
Li YOU
;
Yan ZHUANG
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Anticoagulants;
therapeutic use;
Aspirin;
therapeutic use;
Atorvastatin Calcium;
Cerebral Infarction;
drug therapy;
Drugs, Chinese Herbal;
therapeutic use;
Female;
Heptanoic Acids;
therapeutic use;
Humans;
Male;
Middle Aged;
Piperazines;
therapeutic use;
Pyrroles;
therapeutic use;
Young Adult
- From:
China Journal of Chinese Materia Medica
2014;39(18):3499-3503
- CountryChina
- Language:Chinese
-
Abstract:
To know the characteristics of Shuxuening injection used on cerebral infarction patients in clinical practice, 6 053 cases of Hospital information system (HIS) data from 20 hospitals were analyzed. Using the basic description method and association rules to analysis the data. By analysis the data we found that the average age of cerebral infarction patients who used Shuxuening injection is 67.96, 83.94% of patients were aged 46-80. The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days. It is always combined with aspirin (48.508%), cinepazide maleate injection (22.073%), atorvastatin calcium tablets (18.873%) in clinical practice. When it comes to two drug combinations, it always combined with cinepazide maleate injection and aspirin (8.178%), nicergoline capsules and aspirin (7.63%). Therefore, based on existing data, we give the conclusion that for the treatment of cerebral infarction Shuxuening injection is mainly used for older patients, and is often combination with similar pharmacological effects chemical drugs, which is complied with the guidelines. However, the wrong dose is still exist, doctors should realize the hiding risk.
